Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in...
Brain
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October...
Platform that connects older adults, caregivers and families wins national competition
MONTREAL, Oct. 29, 2025 /CNW/ - Canadian startup Root & Seed has won the 2025 AGE-WELL National Impact Challenge: Implementing...
Apollo Biowellness, Inc., Corporate Status and Merger Update
North Bergen, New Jersey--(Newsfile Corp. - October 29, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to...
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Strategic Shift: Patient Experience Now Healthcare’s Top C-Suite Priority
New Report reveals that 101 hospital and health system leaders prioritize digital health and virtual care to improve access and...
Luminopia Collaborates with Crunchyroll to Continue Building Its Extensive Content Library for Pediatric Lazy Eye Patients
Kids using Luminopia can now watch popular anime shows, further diversifying their content selection CAMBRIDGE, Mass., Oct. 28, 2025...
Liberty Advisor Group Employees Volunteer with Shirley Ryan AbilityLab
CHICAGO, Oct. 28, 2025 /PRNewswire/ -- Employees from Liberty Advisor Group (Liberty), a premier management consulting firm that helps clients tackle...
BrainCo Bionic Hand Inspires a Child’s Journey Forward
BOSTON, Oct. 28, 2025 /PRNewswire/ -- In early September, a young boy named Ma received a brand-new hand — a...
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual acuity...
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the...
Kanazawa University Research: Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells
KANAZAWA, Japan, Oct. 28, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in ACS...
Queen Square Imaging Centre: New technique could improve outcomes for essential tremor patients
BILLINGSHURST, England, Oct. 27, 2025 /PRNewswire/ -- A new study by world-leading neurosurgeons Queen Square Imaging Centre in London has...
Remedy Robotics and Mission Thrombectomy Announce Partnership to Expand Access to Thrombectomy for Stroke with Telerobotics
Remedy Robotics selected as Mission Thrombectomy's exclusive robotics partner to broaden access to life-saving stroke treatment in the U.S. and...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...